Kirk Christopher J. 4
4 · Kezar Life Sciences, Inc. · Filed Jul 24, 2023
Insider Transaction Report
Form 4
Kirk Christopher J.
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2023-07-20$0.90/sh+48,950$44,055→ 431,348 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-07-20−48,950→ 74,411 totalExercise: $0.90Exp: 2025-09-09→ Common Stock (48,950 underlying)
Footnotes (2)
- [F1]Total reflects 914 shares of common stock acquired on November 15, 2022 through the Company's 2018 Employee Stock Purchase Plan.
- [F2]Fully vested and exercisable.